Clik here to view.
TUV莱茵：防疫用品出口疑难解答
深圳 (美国商业资讯)– 疫情当前，哪些种类的防疫物资有出口优势，企业出口需具备哪些资质，欧美市场准入要求是什么……TÜV莱茵大中华区医疗器械服务技术专家、发证官盛甫秀，为广大企业逐一解答。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20200427005473/zh-CN/...
View ArticleClik here to view.
Fight Virus with AI! Pensees Releases Its Intelligent Non-contact Body...
BEIJING As an AI company that focuses on computer vision and IoT technology, Pensees leverages its AIoT technical advantages to release the Intelligent Non-contact Body Temperature Monitoring...
View ArticleClik here to view.
EU MDR Postponed for One Year
SHENZHEN, China As officially stated by EU Parliament on April 17, 2020, the Parliament decided to postpone the application date (May 26, 2020) of new requirements for medical devices (EU...
View ArticleClik here to view.
受新冠肺炎疫情影响，欧盟医疗器械法规（MDR）推迟一年执行
深圳 (美国商业资讯)– 受新冠病毒肺炎（COVID-19）疫情影响，4月24日，《欧洲议会正式公报》发布(EU) 2020/561法规，采纳了欧盟委员会（European Commission）的提议，对医疗器械法规（MDR） [REGULATION (EU)...
View ArticleAVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
Neuraptive Therapeutics宣布FDA核准周围神经损伤患者治疗新药NTX-001的IND申请
费城 (美国商业资讯)–Neuraptive Therapeutics, Inc. (Neuraptive)是一家临床阶段生物技术公司，致力于开发新药和医疗产品以解决周围神经损伤(PNI)治疗中未获满足的需求。该公司今天宣布，美国食品药品管理局(FDA)已核准Neuraptive在研新药(IND) NTX-001用于急性单支横断性PNI患者的申请。 执行副总裁兼研发部主管Evan...
View ArticleClik here to view.
Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support...
DANVERS, Mass. Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand...
View ArticleClik here to view.
TÜV莱茵出席2020首届中国（上海）工业品在线交易节特邀服务商签约仪式
上海 4月28日， 2020首届中国（上海）工业品在线交易节开幕，德国莱茵TÜV集团（以下简称“TÜV莱茵”）出席了同期举行的特邀服务商签约仪式。TÜV莱茵大中华区产品服务事业群副总裁夏波作为独家检测检验认证服务商代表与交易节签约。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20200429005987/zh-CN/...
View ArticleClik here to view.
ニューラプティブ・セラピューティクス、末梢神経損傷患者を治療するための新規手法となるNTX-001のIND申請をFDAが承認と発表
フィラデルフィア （ビジネスワイヤ） — 末梢神経損傷（PNI）の治療における未充足ニーズに対処するための新規の治療薬と医療用製品の開発に専心する臨床段階のバイオテクノロジー企業であるニューラプティブ・セラピューティクス（以下、「ニューラプティブ」）は本日、急性単神経切断PNI患者でのNTX-001に対する当社の新薬臨床試験開始届（IND）を米国食品医薬品局（FDA）が承認したと発表しました。...
View ArticleClik here to view.
Study Finds Noninvasive, Continuous Masimo PVi® Monitoring More Valuable Than...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of Anesthesiology and Reanimation Specialists’ Society in which researchers compared two...
View ArticleClik here to view.
Seoul Viosys Reports First Quarter 2020 Results
ANSAN, South Korea Seoul Viosys Co., Ltd. (“Seoul”) (KOSDAQ:092190), a leading global innovator of short wavelength LED products and technology, today announced KRW 87 billion for consolidated...
View ArticleClik here to view.
アビオメッド、心肺補助技術（ECMO）取得により製品ポートフォリオを拡大、患者転帰を向上へ
米マサチューセッツ州ダンバース （ビジネスワイヤ） — Impella心臓ポンプのメーカーであるアビオメッド（NASDAQ:...
View ArticleClik here to view.
手術中における輸液管理の指針として非侵襲的・連続的Masimo PVi®モニタリングが中心静脈圧測定よりも有益であることを示す研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、Journal of Anesthesiology and Reanimation Specialists’ Society誌に掲載された研究結果を発表しました。研究では、研究者らが、Masimo...
View ArticleClik here to view.
研究发现，无创连续Masimo PVi®监测对指导术中体液处治的价值优于中央静脉压测量
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布了《麻醉与复苏专家学会杂志》发表的一项研究结果，该研究的研究人员比较脊柱骨科手术中两种体液处治方法，包括Masimo PVi®。与有创间歇性中心静脉压(CVP)测量相比，无创连续脉搏灌注变异指数(PVi)监测时“心脏更稳定、补液更少、血管容积状况的评估结果更精准。”1 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Supreme Court Rules in Favor of Hisky; Echosens (Shanghai) to Compensate...
BEIJING Recently, Shanghai Echosens Medical Equipment Technology Co., Ltd. (hereinafter referred to as “Echosens (Shanghai)”) and Fu-Rui Corporation, parent company of Echosens SAS, (hereinafter...
View ArticleClik here to view.
AtriCure Announces Results from CONVERGE IDE Clinical Trial
MASON, Ohio AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the results from the CONVERGE...
View ArticleClik here to view.
AVITA Medical Limited Proposed redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (Company) (ASX:AVH, NASDAQ:RCEL) is pleased to announce that the Federal Court of Australia (Court) has today approved orders to...
View ArticleClik here to view.
Nursing the World to Health: Celebrating Fresenius Kidney Care Nurses’...
HONG KONG Today, on International Nurses Day, Fresenius Medical Care, the world’s leading provider of dialysis products and services, is celebrating the extraordinary contribution that its nurses...
View ArticleClik here to view.
Supreme Court Rules in Favor of Hisky; Echosens (Shanghai) to Compensate...
BEIJING Recently, Shanghai Echosens Medical Equipment Technology Co., Ltd. (hereinafter referred to as “Echosens (Shanghai)”) and Fu-Rui Corporation, parent company of Echosens SAS, (hereinafter...
View ArticleClik here to view.
AVITA Medical to Participate at Oppenheimer’s MedTech Summit
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) today announced that management will participate virtually in the 1-on-1 meetings at the upcoming...
View Article